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Background: Patients with widespread pain, such as in ibromyalgia, are vulnerable for 
depression and anxiety, which composes a relevant public health problem. Identifying 
risk factors for the onset of depression and anxiety is therefore warranted. Objective 
of this study was to determine whether severe pain, maladaptive coping, and poor 
illness perceptions are associated with depressive and anxious symptomatology in 
ibromyalgia.
Method: Consecutive patients referred to an outpatient clinic completed sets of 
physical and psychological questionnaires at baseline and at 18-month follow-up. 
A total of 452 patients with ibromyalgia syndrome (FMS) were eligible for inclusion, and 
subsequently, 280 patients returned the baseline questionnaire. Depressive and anx-
ious symptomatology was measured with the Hospital Anxiety and Depression Scale. 
To measure pain severity, coping style, and illness perceptions, the Fibromyalgia Impact 
Questionnaire, Pain Coping Inventory, and the Illness Perception Questionnaire-Revised 
(IPQ-R) were used, respectively. Multivariable logistic regression analyses, bootstrapping 
and calibration, were performed to examine the association of pain severity, pain coping, 
and illness perception with depressive and anxiety symptoms at follow-up, adjusted 
for sociodemographic variables. Initial level of depressive and anxiety symptoms was 
selected as covariates.
results: Mean age was 42.6 years and 95.4% were female. At 18-month follow-up, 
68 (of the 195) patients were depressed and 80 (of the 197) were anxious. Only the 
IPQ-R subscale “emotional representations” showed a signiicant positive association 
with depressive symptoms at follow-up (OR = 1.10), next to the initial level of depres-
sive symptoms (OR =  1.30). In case of anxiety, only the IPQ-R subscale “treatment 
control” showed a signiicant negative association with anxiety symptoms at follow-up 
(OR = 0.87), next to the initial level of anxiety symptoms (OR = 1.45).
conclusion: Our data suggest that not pain severity or maladaptive coping, but poor 
illness perceptions are important in elevated depressive and anxious symptomatology. 
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Patients with ibromyalgia who think their illness negatively affects their mental well-being 
are at increased risk for more depressive symptoms, and those who think treatment 
of their illness will not be effective are at increased risk for more anxiety symptoms. 
Strengthening illness beliefs and reducing catastrophic thinking, therefore, seem crucial 
factors in the treatment of patients with FMS.
Keywords: pain, coping, illness perceptions, depression, anxiety, ibromyalgia, longitudinal
inTrODUcTiOn
Fibromyalgia syndrome (FMS) is a medical diagnosis of 
unknown etiology mainly characterized by chronic and wide-
spread pain (1). Other symptoms include fatigue, gastrointesti-
nal symptoms, and joint stifness (1–3). Furthermore, a growing 
body of evidence shows a comorbidity of FMS with psychologi-
cal symptoms, particularly with depression and anxiety (2–9): 
lifetime prevalence of depression and anxiety in patients with 
FMS go up to 70 and 60%, respectively (8). Widespread pain 
and mental disorders compose a relevant public health problem 
due to the high economic and societal burden (10–13). A better 
understanding of risk factors for the onset of depressive and anx-
ious symptomatology in FMS might, therefore, be instrumental 
in identifying strategies for prevention and early interventions, 
such as those recommended by the European League Against 
Rheumatism (EULAR) (14, 15). Risk factors for the onset of 
depression and anxiety have been studied longitudinally, and 
include pain, a negative perception of health, dysfunctional 
coping strategies, personality traits (e.g., neuroticism), female 
gender, and lower education (10, 16). his study will focus on 
those factors that have shown to be associated with an increased 
risk of depression and anxiety in chronic pain patients, and 
that might be easily modiiable in treatment: severity of pain 
(10, 17–20), coping strategy (21–23), and illness perceptions 
(24–26). To date, longitudinal studies exploring the contribution 
of all these risk factors in subsequent depressive and anxious 
symptomatology in patients with FMS in one study are lacking.
Widespread pain is characteristic for FMS (1) and thorough 
research exists exploring the association of widespread pain 
and severity of pain with depressive and anxiety disorders 
(10, 17–20). In several cross-sectional studies, among which 
a review and a large survey among 17 countries, multiple pain 
locations were more strongly associated with depression and 
anxiety when compared with one pain location and no pain 
(10, 17, 18). In two longitudinal studies, every additional pain 
location increased the risk of a new onset and recurrence of a 
depressive and/or anxiety disorder with 29 and 7%, respectively 
(19, 20). Moreover, for every increase in the severity of pain the 
risk increased with 57% for new onset and 11% for recurrence of 
depression and/or anxiety (19, 20).
Another risk factor associated with depression and anxiety is 
coping style. Patients with FMS tend to cope passively, such as 
catastrophizing (27, 28). In patients with FMS, pain is indirectly 
associated with depression through its relationship with a passive 
coping style (21). A passive coping style, in turn, is signiicantly 
associated with depression (27). Furthermore, in studies among 
patients with other rheumatic diseases, passive coping strategies, 
including withdrawal and worrying or catastrophizing, were also 
associated with psychological distress (22, 23).
A maladaptive coping style is associated with poor illness 
perceptions (29), that in turn are associated with depressive 
and anxiety symptoms (24–26, 29, 30). In patients with chronic 
widespread pain, negative beliefs about their illness, such as that 
the illness would afect their emotional well-being, were found to 
be associated with an increase of depressive and anxious symp-
tomatology (24, 25). Also, patients with rheumatoid arthritis who 
had negative beliefs about the consequences of their illness were 
more depressed over time (26).
Patients with FMS are characterized by pain in multiple 
locations, or widespread pain. his makes them vulnerable 
for depression and anxiety. However, it is unknown whether 
other characteristics are associated with the onset of depression 
and anxiety. Cross-sectional studies suggest that more severe 
pain, a maladaptive (passive) coping style, and negative illness 
perceptions are related to depression and anxiety in patients 
with (chronic) pain and in patients with rheumatic diseases 
(17, 18, 21–25). FMS is a rheumatic disease, characterized by 
chronic pain, which makes it likely that these factors would 
also play a role in the onset and persistence of depressive and 
anxious symptomatology in this population. However, these 
factors have not been studied in concert and longitudinally in 
FMS before. herefore, a study exploring this association in a 
longitudinal design in FMS is warranted. he aim of this study 
is to examine pain, pain-related coping, and illness perception 
as possible risk factors for depressive and anxious symptoma-
tology in patients with FMS. We hypothesize that more pain, 
passive pain-related coping and poor illness perceptions at 
baseline are associated with more depressive and anxiety 
symptoms in FMS.
MaTerials anD MeThODs
study Design
his study used data from an observational, prospective cohort 
study, with follow-up every 6 months for up to 18 months. Not all 
questionnaires of interest were used at every follow-up measure-
ment, and, therefore, the baseline and 18-month data were used 
for this study.
setting
Data were collected of newly referred consecutive patients to the 
Sint Maartenskliniek rheumatology outpatient clinic, location 
FigUre 1 | Flowchart of the inclusion procedure.
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Nijmegen and Woerden, the Netherlands, between December 
2011 and November 2014.
ethics statement
his study was carried out in accordance with the recommen-
dations of the local medical ethical board with written informed 
consent from all subjects. All subjects gave written informed 
consent in accordance with the Declaration of Helsinki. he 
Institutional Review Board of the University Medical Centre, 
Nijmegen, approved the study (protocol number: 2011/271).
Participants
Patients were included in the cohort ater being classiied as 
having FMS by certiied rheumatologists, who followed the ACR 
guidelines (31, 32) as a diagnostic aid. Other inclusion criteria 
were being 18  years or older and to be able to read and write 
in the Dutch language. here were no exclusion criteria next to 
these inclusion criteria. A total of 452 patients with FMS were 
eligible for inclusion, 311 gave informed consent (68.8%), and 
subsequently, 280 patients returned the baseline questionnaire 
(90.0%). Most frequent dropout reasons were lack of energy or 
concentration, and lack of time. Several patients did not specify 
a reason. For this study, all 280 participants were included. See 
Figure 1 for a lowchart.
Variables
Dependent Variables
he primary outcomes were the presence of depressive symptoms 
(yes/no) and the presence of anxiety symptoms (yes/no). Anxiety 
and depressive symptomology were assessed using the self-rated, 
14-item Hospital Anxiety and Depression Scale (HADS) (33), 
which scores the severity of depressive (HADS-D) and anxiety 
(HADS-A) symptoms, both subscales ranging from 0 to 21. his 
measure was developed speciically for medically ill populations 
and excludes bodily symptoms such as sleep disturbance, fatigue, 
and pain that may be directly attributable to the physical illness 
(33). he HADS has been widely used in people with medical 
illnesses, and its factor structure has been conirmed (34–36). he 
presence of depressive and anxiety symptoms was deined using 
the cutof scores of ≥8 for “possible/probable” depressive or anxi-
ety disorder (33). he cutof score of 8 or more for both subscales 
has shown good predictive value for depressive and anxiety dis-
orders, in somatic, psychiatric, and primary care patients, as well 
as in the general population (37). Both subscales of the HADS 
TaBle 1 | Sociodemographic variables, pain severity, pain-coping strategies, 
and illness perceptions of the ibromyalgia cohort at baseline (N = 280).
Sex (N, %) Male 13 (4.6)
Female 267 (95.4)
Age (mean, SD) 42.61 (11.83)
Education level (N, %) Low 122 (44)
Middle 95 (34)
High 55 (20)
Marital status (N, %) Without partner 59 (21.1)
With partner 218 (77.9)
Pain severity (mean, SD) 6.75 (2.09)
Pain-coping strategies  
(mean, SD)
Passive 43.83 (7.97)
Active 29.16 (4.93)
Illness perceptions (mean, SD) Timeline 23.71 (4.26)
Consequences 19.86 (4.26)
Personal control 20.34 (3.66)
Treatment control 17.00 (2.88)
Illness coherence 15.00 (4.09)
Timeline cyclical 14.69 (3.27)
Emotional representations 15.76 (4.74)
HADS depression (N, %) Normal 162 (57.9)
Possible/probable depression 118 (42.1)
HADS anxiety (N, %) Normal 139 (50.0)
Possible/probable anxiety 140 (50.0)
HADS, Hospital Anxiety and Depression Scale.
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have a good internal consistency (Cronbach’s alpha for HADS-D 
ranges from 0.67 to 0.90; Cronbach’s alpha for HADS-A ranges 
from 0.68 to 0.93) (37).
Predictor Variables
Pain
Pain was assessed using the pain severity subscale of the Dutch 
translation of the Fibromyalgia Impact Questionnaire (FIQ) 
(38, 39), ranging from 0 (no pain) to 10 (severe pain). Reliability 
and validity of the FIQ are good (38).
Pain Coping
Pain coping was measured using the Pain Coping Inventory 
(PCI) (40). he PCI consists of six scales (33 items) measuring 
cognitive and behavioral pain-coping strategies that represent 
two higher order, active, and passive pain-coping dimensions. 
Items are rated according to a 4-point Likert scale ranging 
from 1 (hardly ever) to 4 (very oten) in terms of frequency 
with which strategies are applied when dealing with pain. 
Active pain-coping strategies relect three cognitive-behavioral 
strategies, measuring patient’s eforts to distract themselves 
from pain (distraction, ive items), to reinterpret and transform 
the pain (pain transformation, four items), and to function 
despite pain (reducing demands, three items). Passive pain 
coping relects three cognitive-behavioral strategies, assessing 
behavioral tendencies to restrict functioning (resting, ive items), 
to avoid environmental stimuli (retreating, seven items), and 
catastrophic cognitions about the pain (worrying, nine items). 
A composite score of the active and passive coping dimensions can 
be calculated by taking the mean of the three active and passive 
coping strategies. Conirmatory construct and criterion validity 
of the scales and the second-order structure with respect to active 
and passive pain-coping strategies were supported (40, 41).
Illness Perception
Participants completed the Revised version of the Illness Perception 
Questionnaire (IPQ-R) (42), which assesses patients’ perception 
of their illness. he following seven dimensions of the IPQ-R 
were included: Timeline (e.g., “My illness will last a short time”), 
Timeline cyclical (e.g., “My symptoms come and go in cycles”), 
Consequences (e.g., “My illness is a serious condition”), Personal 
control (e.g., “Nothing I do will afect my illness”), Treatment control 
(e.g., “My treatment will be efective in curing my illness”), Illness 
coherence (e.g., “I do not understand my illness”), and Emotional 
representations (e.g., “My illness makes me feel angry”). he IPQ-R 
is a reliable and well-validated self-report questionnaire (42–44).
Covariates
Initial levels of depressive and anxiety symptoms play an impor-
tant role in subsequent depressive and anxious symptomatology 
(20, 45). herefore, baseline HADS-D score (initial level of depres-
sive symptoms) and baseline HADS-A score (initial level of anxiety 
symptoms) were inserted in the statistical models as covariates.
Sociodemographic Variables
Assessed sociodemographic variables were as follows: sex, age, 
partner status, and education level (primary/lower secondary and 
higher secondary/professional).
statistical Methods
Descriptive statistics were performed to describe the sample at 
baseline, regarding sociodemographic variables, pain severity, 
pain coping, illness perceptions, and depressive and anxiety 
symptoms. To examine which variables predicted depressive 
(n = 68) and anxiety symptoms (n = 80) at 18-month follow-up, 
the following steps were performed: (1) selection of potential 
variables: univariate logistic regression analyses were performed, 
with p <  0.05 as a selection criterion for potential predictive 
variables; (2) multivariable logistic regression analyses using 
backward selection (stopping rule p < 0.2); (3) internal valida-
tion with a bootstrap procedure (500 samples) to estimate the 
amount of over-it; and (4) through calibration, the slope value 
was calculated and used to correct and shrink the regression 
coeicients, the percentage of explained variance (R2), and the 
c-index. Initial level of depressive symptoms and initial level of 
anxiety symptoms were inserted in the models as covariates, 
and their association with the outcome variables was shown 
when signiicant. he models’ performance was assessed by the 
percentage of variance; the agreement between the predicted 
probabilities of the outcome and the observed probabilities in 
the original data (p >  0.05; i.e., Hosmer–Lemeshow test); and 
by the models’ discriminative ability [as relected by the c-index 
that equals the area under the receiver operating characteristic 
curve (AUC)].
resUlTs
Table 1 shows the baseline characteristics of the 280 persons in 
this cohort. Mean age of the study sample was 42.6  years, and 
TaBle 2 | Univariate logistic regression analyses of sociodemographics, pain 
severity, coping strategies, and illness perceptions, for depressive and anxiety 
symptoms.
haDs depression 
(n = 68)
haDs anxiety  
(n = 80)
Or (95% ci) Or (95% ci)
sociodemographics
Sex 1.06 (0.26–4.36) 1.39 (0.34–5.74)
Age 1.00 (0.98–1.03) 0.98 (0.96–1.01)
Having a partner 0.84 (0.41–1.70) 0.75 (0.38–1.49)
Higher educational level 0.61 (0.30–1.24) 0.62 (0.32–1.21)
Pain severity 1.15 (0.99–1.33) 1.13 (0.98–1.30)
coping strategy
Active coping 0.54 (0.26–1.13) 0.60 (0.30–1.20)
Passive coping 2.92 (1.27–6.73)* 2.80 (1.23–6.35)*
illness perceptions
Timeline 1.09 (1.01–1.17)* 1.06 (0.99–1.14)
Timeline cyclical 0.93 (0.85–1.02) 1.03 (0.94–1.12)
Consequences 1.22 (1.12–1.33)* 1.17 (1.08–1.26)*
Personal control 0.89 (0.81–0.97)* 0.94 (0.86–1.02)
Treatment control 0.91 (0.81–1.01) 0.90 (0.81–0.99)*
Illness coherence 0.96 (0.89–1.03) 0.95 (0.89–1.02)
Emotional representations 1.19 (1.10–1.28)* 1.19 (1.10–1.28)*
covariates
HADS baseline depression score 1.37 (1.24–1.52)* 1.21 (1.11–1.32)*
HADS baseline anxiety score 1.21 (1.12–1.32)* 1.44 (1.30–1.61)*
HADS, Hospital Anxiety and Depression Scale.
*Signiicant at the 0.05 level.
TaBle 3 | Multivariable logistic model predicting depressive and anxiety 
symptoms at 18-month follow-up.
haDs depression 
(n = 68)
haDs anxiety 
(n = 80)
Or p-Value Or p-Value
HADS baseline depression 
score
1.30 <0.0001
HADS baseline anxiety score 1.45 <0.0001
Treatment control 0.87 0.04
Emotional representations 1.10 0.03
Model performance Model corrected Model corrected
Explained variance 
(Nagelkerke R2)
0.35 0.30 0.44 0.40
c-Index 0.82 0.80 0.85 0.83
calibration
Hosmer and Lemeshow χ2 = 13.85 χ2 = 13.05
Slope value 0.89 0.90
HADS, Hospital Anxiety and Depression Scale.
5
de Heer et al. Poor Illness Perceptions and Fibromyalgia
Frontiers in Psychiatry | www.frontiersin.org November 2017 | Volume 8 | Article 217
95.4% were female. Mean pain severity was 6.75 on a 10-point 
Likert scale. Of the participants, 118 (42.1%) had a possible or 
probable depressive disorder, and 140 (50%) had a possible or 
probable anxiety disorder at baseline.
Table 2 shows the univariate associations between all predic-
tor variables and the covariates, with depressive and anxious 
symptomatology at 18-month follow-up (n = 68 for depressive 
symptoms; n = 80 for anxiety symptoms). Regarding the depres-
sion outcome, a passive coping style (OR = 2.92), and the IPQ 
subscales “timeline” (OR = 1.09), “consequences” (OR = 1.22), 
“personal control” (OR = 0.89), and “emotional representations” 
(OR = 1.19) had a signiicant univariate association with a pos-
sible/probable depressive disorder at 18-month follow-up. he 
covariates’ initial level of depressive symptoms and initial level of 
anxiety symptoms also had a signiicant univariate association with 
a possible/probable depressive disorder at 18-month follow-up 
(OR = 1.37 and OR = 1.21, respectively). Ater logistic regression 
with backward selection (Table 3), the IPQ subscale “emotional 
representations” (OR =  1.10) was signiicantly associated with 
possible/probable depressive disorder at 18-month follow-up, 
next to initial level of depressive symptoms (OR = 1.30). hus, 
subjects who respond emotionally regarding their illness and 
have more initial depressive symptoms at baseline are at increased 
risk for a possible or probable depressive disorder at follow-up. 
Together, these variables in the regression model accounted for 
30% of the variance of the depression score at follow-up. he 
overall it of the derived model was good (χ2 = 13.85, p = 0.09).
Regarding anxiety outcome, a passive coping style 
(OR = 2.80), and the IPQ subscales “consequences” (OR = 1.17), 
“treatment control” (OR  =  0.90), and “emotional representa-
tions” (OR = 1.19) had a signiicant univariate association with 
a possible/probable anxiety disorder at 18-month follow-up 
(Table  2). he covariates’ initial level of depressive symptoms 
and initial level of anxiety symptoms also had a signiicant uni-
variate association with a possible/probable anxiety disorder at 
18-month follow-up (OR = 1.21 and OR = 1.44, respectively). 
Ater logistic regression with backward selection, treatment 
control (OR = 0.87) was signiicantly associated with possible/
probable anxiety disorder at 18-month follow-up, next to initial 
level of anxiety symptoms (OR = 1.45) (Table 3). hus, subjects 
who think that their treatment is not efective regarding their ill-
ness and have more anxiety symptoms at baseline are at increased 
risk for a possible or probable anxiety disorder. Together, these 
variables in the regression model accounted for 40% of the 
variance of the anxiety score at follow-up. he overall it of the 
derived model was good (χ2 = 13.05, p = 0.11).
DiscUssiOn
To the authors’ knowledge, this is the irst study to document 
on pain, illness perception, and coping style as risk factors for 
depressive and anxious symptomatology in patients with FMS. 
he results here indicate that patients with FMS who believe 
their illness will have a negative efect on their mental well-being, 
who also have elevated levels of depressive symptoms, are more 
likely to be depressed on subsequent occasions. Furthermore, 
patients with FMS who think that treatment of their illness will 
not be efective and who also have elevated levels of anxiety 
symptoms are more likely to be anxious on subsequent occa-
sions. Our hypothesis that poor illness perceptions are a risk 
factor for depressive and anxious symptomatology is therefore 
conirmed.
Only illness perceptions and initial level of afective symp-
toms were found to play a signiicant role in depressive and 
anxious symptomatology, suggesting that these factors are 
6de Heer et al. Poor Illness Perceptions and Fibromyalgia
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possibly more important than other well-known risk factors, 
such as pain, which is contrary to what we expected. hese 
indings are consistent with previous research in similar 
populations. For example, patients with chronic (widespread) 
pain who had a strong belief that their illness would afect their 
mental well-being were more likely to report depressive and 
anxiety symptoms (24, 25), whereas pain intensity did not show 
such an association (24). In patients with rheumatoid arthritis, 
the patients’ beliefs and emotional responses to their illness 
were key factors explaining the association between pain and 
depression (46). Furthermore, in two large longitudinal studies, 
the association between pain and new onset and recurrence 
of depression and anxiety were mediated by (subthreshold) 
depressive symptoms (19, 20). his could explain our inding 
that not pain severity, but negative cognitions about the illness 
and the initial level of afective symptoms are more important 
as risk factors in the development of subsequent depressive and 
anxious symptomatology. Neurobiological abnormalities might 
also play a role, which persists in patients who have experienced 
strong negative emotions, possibly through negative biases in 
the processing of emotional information (47). On the other 
hand, pain and emotion share neuronal networks, and pain, one 
of the main characteristics of FMS, might cause a dysregulation 
in the neuronal network associated with emotion (48). hus, 
patients with FMS who experience negative afective symp-
toms and negative perceptions regarding their illness might, 
therefore, have developed neurobiological abnormalities, 
making them vulnerable for subsequent depressive and anxious 
symptomatology.
Contrary to what we expected, a passive coping style was 
not a signiicant risk factor for depressive and anxiety symp-
toms, in contrast to a previous study in patients with FMS 
(21). However, they used another construct of passive coping, 
emphasizing on emotion-focused strategies, whereas passive 
coping in this study was mostly characterized by avoidant strat-
egies. In a study in patients with systemic sclerosis, a rheumatic 
disease, emotion-focused coping had a strong association with 
depressive symptoms, whereas avoidant focused coping did 
not (22). Furthermore, in patients with chronic heart failure, 
an avoidant coping style was indirectly associated with depres-
sion and anxiety through poor illness perceptions (29), which 
might explain our indings. his might suggest that emotional 
components of coping with an illness are more important than 
other maladaptive forms of coping. In our study, passive cop-
ing consisted of three cognitive-behavioral strategies, one of 
them being catastrophizing or worrying, which is an emotional 
component also. herefore, future studies should explore the 
subcategories of passive coping to explore whether the emo-
tional components of coping are indeed more important than 
other components.
Strengths of this study are the longitudinal design and the large 
sample size. However, several limitations need to be addressed. 
he sample of this study consisted of patients with FMS, which 
limits the generalizability to other populations. However, com-
parable results were found in other rheumatologic populations 
(22, 24, 25, 46). his might suggest that our results are generaliz-
able to populations characterized by a chronic disease. In this 
study, the HADS, which was developed speciically for medically 
ill populations, was used to measure depressive and anxious 
symptomatology. Although this instrument has good internal 
consistency and can be used as case inding for depressive and 
anxiety disorders (37), and is widely used in rheumatologic 
populations, no inferences could be made whether patients met 
criteria for a depressive or anxiety disorder. For such purposes, 
diagnostic (semi)structured interviews need to be used, such 
as the Mini-International Neuropsychiatric Interview (49) or 
Composite International Diagnostic Interview (50). In addition, 
we used a single self-reported questionnaire (FIQ) to measure 
pain severity, which prevents us to make inferences of other 
aspects of functioning and well-being, such as quality of life. 
Besides, it is possible that factors not studied here might play 
a crucial role in depressive and anxious symptomatology in 
patients with FMS. Received treatment, whether it is physical 
(51–54), psychological, or pharmacological (55), can inluence 
both depressive as anxiety symptoms. Patients in this study 
received advice for treatment, based on the recommendations of 
the EULAR (14, 15), ater the baseline measurement. Treatment 
advice could be referral (back) to the general practitioner, physi-
otherapist, psychologist, or a multimodal rehabilitation program. 
Unfortunately, no information was available whether this advice 
was followed, or if another treatment was received other than 
advised. We were, therefore, unable to make any inferences on 
the efect of treatment on depression and anxiety. Other factors 
that might inluence depressive and anxious symptomatology 
are medication use, comorbidity with other chronic diseases 
(56), and perceived social support (57). Unfortunately, due to 
the limited sample size at follow-up (68 patients for depressive 
symptoms and 80 for anxiety symptoms), it was not possible to 
include more factors in the statistical models. Future research 
with larger sample sizes is needed. A larger sample size is also 
necessary to examine the incidence of depressive and anxious 
symptomatology, by excluding those patients with depressive 
and anxiety symptoms at baseline. he sample size of this study 
was too small, unfortunately.
cOnclUsiOn
Our study highlights the importance of illness perceptions in 
the development of depressive and anxious symptomatology in 
patients with FMS. Developing treatment interventions aimed at 
modiication of poor illness perceptions is therefore of interest. 
It has been shown that interventions focusing on illness percep-
tions, such as cognitive treatment and illness perception focused 
intervention, is efective in improving maladaptive perceptions 
in patients with chronic low back pain (58), and even has a 
positive efect on depressive and anxious symptomatology (59). 
In addition, cognitive behavior therapy focusing on catastro-
phizing has shown to be efective at increasing acceptance of the 
illness and global functioning in patients with FMS (60). Our 
indings corroborate the recommendations of the EULAR for 
psychological treatment, such as cognitive behavior therapy, in 
case of depressed mood (15). hus, strengthening illness beliefs 
and reducing catastrophic thinking seem to be important factors 
in the treatment of patients with FMS, allowing them to improve 
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their health. Future research should further explore the efects of 
such interventions.
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